GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Probi AB (OSTO:PROB) » Definitions » LT-Debt-to-Total-Asset

Probi AB (OSTO:PROB) LT-Debt-to-Total-Asset : 0.02 (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Probi AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Probi AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.02.

Probi AB's long-term debt to total assets ratio declined from Mar. 2023 (0.03) to Mar. 2024 (0.02). It may suggest that Probi AB is progressively becoming less dependent on debt to grow their business.


Probi AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Probi AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Probi AB LT-Debt-to-Total-Asset Chart

Probi AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.03 0.04 0.03 0.03

Probi AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.03 0.03 0.02

Probi AB LT-Debt-to-Total-Asset Calculation

Probi AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=38.212/1490.443
=0.03

Probi AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=36.905/1537.135
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Probi AB  (OSTO:PROB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Probi AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Probi AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Probi AB (OSTO:PROB) Business Description

Traded in Other Exchanges
Address
Ideongatan 1 A, Lund, SWE, SE-223 70
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. The company's research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).

Probi AB (OSTO:PROB) Headlines

No Headlines